Increasing maternal age is not a significant cause of false-positive results for monosomy X in non-invasive prenatal testing.

Publisher: Wiley Country of Publication: England NLM ID: 8106540 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0223 (Electronic) Linking ISSN: 01973851 NLM ISO Abbreviation: Prenat Diagn Subsets: MEDLINE

Original Publication: Chichester, [Sussex]; New York : Wiley, c1981-

Maternal Age*; Noninvasive Prenatal Testing/*statistics & numerical data ; Turner Syndrome/*diagnosis; Adult ; False Positive Reactions ; Female ; Humans ; Pregnancy ; Retrospective Studies

Objective: The accuracy of cell-free DNA aneuploidy screening varies by the chromosome assessed. The positive predictive value is consistently low for monosomy X (MX), at less than 30%. This study aims to investigate maternal age and other possible predictors of false-positive MX screening results in order to guide pre-test and post-test counselling.
Methods: A total of 52 499 NIPT samples were tested over 69 months, across three specialist obstetric services. Outcome data were available for 96 out of 107 cases high risk for MX. Cytogenetic outcomes were compared to clinical and demographic data to look for trends that may indicate higher likelihood of a false-positive NIPT result.
Results: The likelihood of a false-positive MX result significantly increased with the absence of ultrasound features suggestive of MX and with lower PAPP-A levels. Non-significant trends towards false-positive results were identified with increased maternal age, increased body mass index and Caucasian ethnicity.
Conclusion: Maternal age is not a reliable predictor of a false-positive result. Assessment of ultrasound findings and placental serology in the first trimester is important for appropriate post-test counselling and should continue to be a part of screening even when NIPT is used as a first-tier screening test.
(© 2020 John Wiley & Sons Ltd.)

Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn. 2013;33(6):569-574.
Hartwig TS, Ambye L, Sørensen S, Jørgensen FS. Discordant non-invasive prenatal testing (NIPT)-a systematic review. Prenat Diagn. 2017;37(6):527-539.
Mazloom AR, Džakula Ž, Oeth P, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn. 2013;33(6):591-597.
Kajii T, Ohama K. Inverse maternal age effect in monosomy X. J Hum Genet. 1979;51(2):147-151.
Warburton D, Kline J, Stein Z, Susser M. Monosomy X: a chromosomal anomaly associated with young maternal age. Lancet. 1980;315(8161):167-169.
Hook EB, Warburton D. The distribution of chromosomal genotypes associated with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum Genet. 1983;64(1):24-27.
Nielsen J, Wohlert M. Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in Århus. Denmark J Hum Genet. 1991;87(1):81-83.
Stochholm K, Juul S, Juel K, Naeraa RW, Højbjerg Gravholt C. Prevalence, incidence, diagnostic delay, and mortality in turner syndrome. J Clin Endocrinol Metab. 2006;91(10):3897-3902.
Taylor-Phillips S, Freeman K, Geppert J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 2016;6(1):e010002.
Petersen AK, Cheung SW, Smith JL, et al. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. Am J Obstet Gynecol. 2017;217(6):691-e1.
McLennan A, Palma-Dias R, da Silva Costa F, Meagher S, Nisbet DL, Scott F. Noninvasive prenatal testing in routine clinical practice - an audit of NIPT and combined first-trimester screening in an unselected Australian population. Aust N Z J Obstet Gynaecol. 2016;56(1):22-28.
Kornman L, Palma-Dias R, Nisbet D, et al. Non-invasive prenatal testing for sex chromosome aneuploidy in routine clinical practice. Fetal Diagn Ther. 2018;44(2):85-90.
Xue Y, Zhao G, Li H, et al. Non-invasive prenatal testing to detect chromosome aneuploidies in 57,204 pregnancies. Mol Cytogenet. 2019;12(1):29.
Bianchi DW, Parsa S, Bhatt S, et al. Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet Gynecol. 2015;125(2):375-382.
Quezada MS, Gil MM, Francisco C, Orosz G, Nicolaides KH. Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10-11 weeks' gestation and the combined test at 11-13 weeks. Ultrasound Obstet Gynecol. 2015;45(1):36-41.
Bianchi DW, Prosen T, Platt LD, et al. Maternal blood is source to accurately diagnose fetal aneuploidy (MELISSA) study group. Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma. Obstet Gynecol. 2013;121(5):1057-1062.
Sharp A, Robinson D, Jacobs P. Age-and tissue-specific variation of X chromosome inactivation ratios in normal women. Hum Genet. 2000;107(4):343-349.
Russell LM, Strike P, Browne CE, Jacobs PA. X chromosome loss and ageing. Cytogenet Genome Res. 2007;116(3):181-185.
Machiela MJ, Zhou W, Karlins E, et al. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nat Commun. 2016;7(1):1-9.
Syngelaki A, Hammami A, Bower S, Zidere V, Akolekar R, Nicolaides KH. Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2019;54(4):468-476.
National Health and Medical Research Council. Ethical Considerations in Quality Assurance and Evaluation Activities. 2014. https://www.nhmrc.gov.au/about-us/resources/ethical-considerations-quality-assurance-and-evaluation-activities.
Chen KM, White K, Shabbeer J, Schmid M. Maternal age trends support uptake of non-invasive prenatal testing (NIPT) in the low-risk population. J Matern Fetal Neonatal Med. 2019;32(23):4039-4042.
Bowman-Smart H, Savulescu J, Mand C, et al. ‘Small cost to pay for peace of mind’: women's experiences with non-invasive prenatal testing. Aust N Z J Obstet Gynaecol. 2019;59:649-655.
Spencer K, Tul N, Nicolaides KH. Maternal serum free β-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn. 2000;20(5):390-394.
Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn. 2002;22(9):778-782.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH. Fetal nasal bone in screening for trisomies 21, 18 and 13 and turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009;33(3):259-264.
Scott F, Coates A, McLennan A. Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels. Aust N Z J Obstet Gynaecol. 2009;49(3):258-262.
Scott F, Bonifacio M, Sandow R, Ellis K, Smet ME, McLennan A. Rare autosomal trisomies: important and not so rare. Prenat Diagn. 2018;38(10):765-771.
Scott FP, Menezes M, Palma-Dias R, et al. Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. J Matern Fetal Neonatal Med. 2018;31(14):1865-1872.
Mardy A, Wapner RJ. Confined placental mosaicism and its impact on confirmation of NIPT results. Am J Med Genet Part C Semin Med Genet. 2016;172(2):118-122.
Beta J, Zhang W, Geris S, Kostiv V, Akolekar R. Procedure related risk of miscarriage from chorionic villus sampling and amniocentesis. Ultrasound Obstet Gynecol. 2019;54(4):452-457.
Akolekar R, Beta J, Picciarelli G, Ogilvie C, D'Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;45(1):16-26.
Wulff CB, Gerds TA, Rode L, et al. Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies. Ultrasound Obstet Gynecol. 2016;47(1):38-44.
Bardi F, Bosschieter P, Verheij J, et al. Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening? Prenat Diagn. 2020;40(2):197-205.
Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004;66(3):411-421.

Date Created: 20200717 Date Completed: 20211020 Latest Revision: 20211020

20221213

10.1002/pd.5790

32673423